Aug 27, 2026 | Press Releases
SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) (“Valion Bio” or the “Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding...
Aug 13, 2026 | Press Releases
Potential Fourth-Quarter 2026 Decision Could Mark Entolimod’s First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry begins technical assessment • Regulatory...
Aug 12, 2026 | Press Releases
AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned to start this weekNear-Term Program MilestonesStudy...
Jul 22, 2026 | Press Releases
Government acceptance initiates formal regulatory review of Entolimod under Ukraine’s Regulatory Equivalency pathway, with a potential review expected in as few as 45- to 60-days.Ukraine Ministry of Health Accepts Entolimod for Formal Review – Following...
Jul 20, 2026 | Press Releases
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio’s Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome. Highlights Independent...